

Reference:	FOI.15797.24
Subject:	Chronic Lymphocytic Leukaemia (CLL)
Date of Request:	22 October 2024

Requested:

1. How many **newly diagnosed** patients with chronic lymphocytic leukaemia (CLL) have **started first-line treatment** in your Trust or Centre during the 6-month period February 2024 to July 2024?
2. How many of these **newly diagnosed** patients with CLL **received chemoimmunotherapy (CIT) as first-line treatment**?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

3. Please complete the table below with how many **newly diagnosed** patients with CLL have **started first-line treatment** with each of the following CITs during the 6-month period February 2024 to July 2024
 - FCR (fludarabine + cyclophosphamide + rituximab)
 - FR (fludarabine + rituximab)
 - BR (bendamustine + rituximab)
 - Bendamustine monotherapy
 - RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
 - Obinutuzumab ± chlorambucil
 - Rituximab + chlorambucil
 - Ofatumumab
 - Other – please specify

Note: this should only include **newly diagnosed** patients with CLL who have **started first-line treatment during the 6-month window**

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	
FR	
BR	
Bendamustine monotherapy	
R-CHOP	
Obinutuzumab ± chlorambucil	
Rituximab + chlorambucil	
Chlorambucil monotherapy	
Rituximab monotherapy	
Ofatumumab	
Other – please specify	

Response:

1. Hywel Dda University Health Board (UHB) can confirm that ten (10) new patients diagnosed with CLL started first line treatment during the six (6) month period from 1 February 2024 to 31 July 2024, as is recorded on Chemocare.
2. The UHB is unable to provide the requested information as it is not held within the Chemocare system.
3. The UHB is unable to provide the requested information as it is not held within the Chemocare system.